Aggregated
33% success rate- Bullish
- 0
- Hold
- 0
- Bearish
- 0
Ladenburg Thalmann
A Ladenburg Thalmann analyst with 9 tracked ratings across 9 distinct tickers has a 33.3% success rate on the captured sample, focusing on two sources.
Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.
| Ticker | Date | Rating | Price target | Source |
|---|---|---|---|---|
| CLRB | 2026-05-15 | buy | $10.00 | Aggregated |
| DCOY | 2026-01-23 | buy | $2.50 | Aggregated |
| NXTC | 2025-11-07 | buy | $18.00 | Aggregated |
| CRDF | 2025-07-08 | buy | $19.00 | Aggregated |
| CRDFCARDIFF ONCOLOGY INC | 2025-07-08 | unknown | $19.00 | Aggregated |
| NVCR | 2025-07-08 | buy | $30.00 | Aggregated |
| NVCRNOVOCURE LTD | 2025-07-08 | unknown | $30.00 | Aggregated |
| ORIC | 2025-07-08 | buy | $15.00 | Aggregated |
| ORICORIC PHARMACEUTICALS INC | 2025-07-08 | unknown | $15.00 | Aggregated |
| Ticker | Ratings | Last rating | Sources |
|---|---|---|---|
| CLRB | 1 | 2026-05-15 | Aggregated |
| DCOY | 1 | 2026-01-23 | Aggregated |
| NXTC | 1 | 2025-11-07 | Aggregated |
| CRDF | 1 | 2025-07-08 | Aggregated |
| CRDFCARDIFF ONCOLOGY INC | 1 | 2025-07-08 | Aggregated |
| NVCR | 1 | 2025-07-08 | Aggregated |
| NVCRNOVOCURE LTD | 1 | 2025-07-08 | Aggregated |
| ORIC | 1 | 2025-07-08 | Aggregated |
| ORICORIC PHARMACEUTICALS INC | 1 | 2025-07-08 | Aggregated |